
Hamid Moradi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6105289/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Translational Research, 2009, 153, 77-85.	5.0	152
2	Cardiovascular Burden Associated with Uremic Toxins in Patients with Chronic Kidney Disease. American Journal of Nephrology, 2013, 38, 136-148.	3.1	135
3	Reverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric Population. Journal of the American Medical Directors Association, 2015, 16, 933-939.	2.5	102
4	Mechanisms of dyslipidemia of chronic renal failure. Hemodialysis International, 2006, 10, 1-7.	0.9	101
5	In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney International, 2009, 76, 437-444.	5.2	98
6	Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrology Dialysis Transplantation, 2014, 29, 1554-1562.	0.7	84
7	Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench. Progress in Cardiovascular Diseases, 2018, 61, 168-181.	3.1	73
8	LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis, and Vasculopathy in a Rat Model of Chronic Kidney Disease. Journal of Cardiac Failure, 2018, 24, 266-275.	1.7	71
9	Red Cell Distribution Width and Mortality inÂHemodialysisÂPatients. American Journal of Kidney Diseases, 2016, 68, 110-121.	1.9	70
10	Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword. , 2013, 23, 203-206.		60
11	Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrology Dialysis Transplantation, 2016, 31, 1310-1319.	0.7	51
12	Association of Adiponectin With Body Composition and Mortality in Hemodialysis Patients. American Journal of Kidney Diseases, 2015, 66, 313-321.	1.9	49
13	Inhibition of intestinal ascorbic acid uptake by lipopolysaccharide is mediated via transcriptional mechanisms. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 556-565.	2.6	44
14	Reverse Cholesterol Transport Pathway in Experimental Chronic Renal Failure. American Journal of Nephrology, 2009, 30, 147-154.	3.1	43
15	Association of Serum Triglyceride to HDL Cholesterol Ratio with All-Cause and Cardiovascular Mortality in Incident Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 591-602.	4.5	42
16	Skeletal muscle mitochondrial depletion and dysfunction in chronic kidney disease. International Journal of Clinical and Experimental Medicine, 2013, 6, 532-9.	1.3	42
17	Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD). Nephrology Dialysis Transplantation, 2009, 24, 2541-2546.	0.7	38
18	Association of serum vitamin B12 and folate with mortality in incident hemodialysis patients. Nephrology Dialysis Transplantation, 2017, 32, 1024-1032.	0.7	36

Hamid Moradi

#	Article	IF	CITATIONS
19	Cannabinoids and the kidney: effects in health and disease. American Journal of Physiology - Renal Physiology, 2017, 313, F1124-F1132.	2.7	33
20	Salutary Effects of Hemodialysis on Low-Density Lipoprotein Proinflammatory and High-Density Lipoprotein Anti-inflammatory Properties in Patient With End-Stage Renal Disease. Journal of the National Medical Association, 2011, 103, 524-533.	0.8	30
21	Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease. Cannabis and Cannabinoid Research, 2019, 4, 10-20.	2.9	29
22	Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury. Cannabis and Cannabinoid Research, 2016, 1, 218-228.	2.9	27
23	Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Frontiers in Bioscience - Landmark, 2018, 23, 146-161.	3.0	27
24	Racial and Ethnic Disparities in the Obesity Paradox. American Journal of Kidney Diseases, 2018, 72, S26-S32.	1.9	20
25	Inverse Association Between Serum Non–Highâ€Đensity Lipoprotein Cholesterol Levels and Mortality in Patients Undergoing Incident Hemodialysis. Journal of the American Heart Association, 2018, 7, .	3.7	20
26	Association of Serum Lipids with Outcomes in Hispanic Hemodialysis Patients of the West versus East Coasts of the United States. American Journal of Nephrology, 2015, 41, 284-295.	3.1	19
27	Could high-density lipoprotein cholesterol predict increased cardiovascular risk?. Current Opinion in Endocrinology, Diabetes and Obesity, 2017, 24, 140-147.	2.3	19
28	<scp>ESRD</scp> â€induced dyslipidemia—Should management of lipid disorders differ in dialysis patients?. Seminars in Dialysis, 2018, 31, 398-405.	1.3	19
29	Serum triglycerides and mortality risk across stages of chronic kidney disease in 2 million U.S. veterans. Journal of Clinical Lipidology, 2019, 13, 744-753.e15.	1.5	19
30	Effect of Chronic Renal Failure on Arginase and Argininosuccinate Synthetase Expression. American Journal of Nephrology, 2006, 26, 310-318.	3.1	16
31	Associations of Systolic Blood Pressure With Incident CKD G3-G5: A Cohort Study of South Korean Adults. American Journal of Kidney Diseases, 2020, 76, 224-232.	1.9	16
32	Increments in serum high-density lipoprotein cholesterol over time are not associated with improved outcomes in incident hemodialysis patients. Journal of Clinical Lipidology, 2018, 12, 488-497.	1.5	15
33	Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease. Diagnostics, 2018, 8, 71.	2.6	15
34	Association of Pre-End-Stage Renal Disease Serum Albumin With Post-End-Stage Renal Disease Outcomes Among Patients Transitioning to Dialysis. , 2019, 29, 310-321.		15
35	Association of Serum Paraoxonase/Arylesterase Activity With All-Cause Mortality in Maintenance Hemodialysis Patients. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4848-4856.	3.6	14
36	Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Translational Research, 2013, 161, 477-485.	5.0	12

Hamid Moradi

#	Article	IF	CITATIONS
37	Association of Pre-End-Stage Renal Disease Hemoglobin with Early Dialysis Outcomes. American Journal of Nephrology, 2018, 47, 333-342.	3.1	12
38	Cerebral microbleeds and cognitive decline in a hemodialysis patient: Case report and review of literature. Hemodialysis International, 2015, 19, E1-7.	0.9	10
39	Functional thiamine deficiency in end-stage renal disease: malnutrition despite ample nutrients. Kidney International, 2016, 90, 252-254.	5.2	10
40	Serum high density lipoprotein cholesterol level and risk of death: let's avoid the extremes. Journal of Thoracic Disease, 2017, 9, 4849-4852.	1.4	9
41	Serum Endocannabinoid Levels in Patients With End-Stage Renal Disease. Journal of the Endocrine Society, 2019, 3, 1869-1880.	0.2	9
42	Circulating Endocannabinoids and Mortality in Hemodialysis Patients. American Journal of Nephrology, 2020, 51, 86-95.	3.1	9
43	Effect of resveratrol on progression of polycystic kidney disease: a case of cautious optimism. Nephrology Dialysis Transplantation, 2016, 31, 1755-1758.	0.7	7
44	Histone deacetylase inhibitors regulate vitamin C transporter functional expression in intestinal epithelial cells. Journal of Nutritional Biochemistry, 2021, 98, 108838.	4.2	7
45	Cannabis Use and Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease Transitioning to Dialysis. Cannabis and Cannabinoid Research, 2023, 8, 138-147.	2.9	4
46	RNA Interference Targeting Liver Angiopoietin-Like Protein 3 Protects from Nephrotic Syndrome in a Rat Model Via Amelioration of Pathologic Hypertriglyceridemia. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 428-435.	2.5	3
47	Renoprotective mechanisms of ischemic postconditioning in ischemia-reperfusion injury: improved mitochondrial function and integrity. Nephrology Dialysis Transplantation, 2013, 28, 2667-2669.	0.7	2
48	Feasibility and acceptability of a structured quality by design approach to enhancing the rigor of clinical studies at an academic health center. Journal of Clinical and Translational Science, 2021, 5, e175.	0.6	2
49	Altered lipid metabolism and serum lipids in chronic kidney disease. , 2022, , 43-60.		2
50	Introduction: Precision Medicine in End-Stage Kidney Disease and Personalized Renal Replacement Therapy: Challenges and Unmet Need. Seminars in Nephrology, 2018, 38, 315-316.	1.6	1
51	Hemodynamic and Laboratory Changes during Incremental Transition from Twice to Thrice-Weekly Hemodialysis. CardioRenal Medicine, 2020, 10, 97-107.	1.9	1
52	Impact of Circulating <i>N</i> -Acylethanolamine Levels with Clinical and Laboratory End Points in Hemodialysis Patients. American Journal of Nephrology, 2021, 52, 59-68.	3.1	1
53	Arrangement Optimization of Robotic surgery Arms at Sina _{flex} surgical platform. , 2021, , .		1